search
Back to results

Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV

Primary Purpose

Respiratory Distress Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
NCPAP
NIPPV
Sponsored by
Uludag University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Respiratory Distress Syndrome focused on measuring NCPAP, NIPPV, LISA

Eligibility Criteria

24 Weeks - 29 Weeks (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Gestational age 24 -29 week
  • Clinical and radiological diagnosis of RDS
  • Born in a hospital with a study center
  • Spontaneous breathing
  • Within the first 6 hours
  • Non-invasive ventilation and FiO2 requirement >0.30
  • Parental concent

Exclusion Criteria:

  • Major congenital malformations
  • Need of mechanical ventiation
  • Need of entubation in delivery room
  • Air weak syndrome
  • No parental concent

Sites / Locations

  • Hilal OzkanRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

NCPAP

NIPPV

Arm Description

Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94. Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O.

Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94. Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O.

Outcomes

Primary Outcome Measures

Treatment failure within 72 hours after randomization 72 hours after randomization
Need for invasive mechanical ventilation

Secondary Outcome Measures

Rate of bronchopulmonary dysplasia
defined according to the NICHD definition

Full Information

First Posted
December 15, 2020
Last Updated
January 18, 2021
Sponsor
Uludag University
search

1. Study Identification

Unique Protocol Identification Number
NCT04698473
Brief Title
Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV
Official Title
Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV in Premature Babies: CURLISPAP Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Uludag University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Non invasive ventilation is important in the care of preterm infants with respiratory failure, and surfactant treatment can be use with non invasive ventilation. However, there is no consensus on the best non-invasive ventilation mode for surfactant treatment in preterm infants. Objective: To compare the effectiveness of nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (CPAP) in preterm infants ≤ 29 week gestational age.
Detailed Description
This CURLISPAP study was a multicenter, randomized controlled study at six level III neonatal intensive care units (NICUs) in Turkey. The protocol was approved by the ethics committee of each participating centre and Turkish Ministry of Health, Turkish Medicines and Medical Devices Agency. Non invasive ventilated preterm infants with respiratory distress syndrome and gestational age from 241/7 weeks to 296/7 weeks were enrolled within 6 h of birth. Infants with major congenital malformations, need of mechanical ventiation, need of entubation in delivery room and lack of parental consent were excluded. Enrolled infants will randomize into two study groups (NIPPV group and CPAP group). The short binasal prongs will use as interface. For all the groups, if the fraction of inspired oxygen (FiO2) requirement is persistently higher than 0.30 target SpO2 90-94%. For all groups Surfactant by "LISA" technique and with special catheter (LISAcath, Chiesi Pharmaceutics) of surfactant (Curosurf, Chiesi Pharmaceutics) 200 mg/kg. The primary end-point, need of mechanical ventilation within 72 hours following surfactant treatment, will compared between the groups. Short and long-term neonatal outcomes will also evaluate.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Distress Syndrome
Keywords
NCPAP, NIPPV, LISA

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
170 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NCPAP
Arm Type
Active Comparator
Arm Description
Ventilator-derived NCPAP will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-94. Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O.
Arm Title
NIPPV
Arm Type
Active Comparator
Arm Description
Ventilator-derived NIPPV will be administered using binasal prongs. Standard Devices or infant flow-driver device. Initial NIPPV settings are: PEEP:6 cmH2O, PIP: 15 cmH2O, Rate: 30-40/ bpm and FiO2: adjusted to keep preductal sPO2 between %90-94. Failure is defined as FiO2 requirement of >%50, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>60 cmH2O.
Intervention Type
Other
Intervention Name(s)
NCPAP
Intervention Description
NCPAP infants will be randomized into two different non invasive ventilation groups
Intervention Type
Other
Intervention Name(s)
NIPPV
Intervention Description
NIPPV NCPAP infants will be randomized into two different non invasive ventilation groups
Primary Outcome Measure Information:
Title
Treatment failure within 72 hours after randomization 72 hours after randomization
Description
Need for invasive mechanical ventilation
Time Frame
within 72 hours after randomization
Secondary Outcome Measure Information:
Title
Rate of bronchopulmonary dysplasia
Description
defined according to the NICHD definition
Time Frame
36 weeks of postmenstrual age ]

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Weeks
Maximum Age & Unit of Time
29 Weeks
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Gestational age 24 -29 week Clinical and radiological diagnosis of RDS Born in a hospital with a study center Spontaneous breathing Within the first 6 hours Non-invasive ventilation and FiO2 requirement >0.30 Parental concent Exclusion Criteria: Major congenital malformations Need of mechanical ventiation Need of entubation in delivery room Air weak syndrome No parental concent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
hilal ozkan, professor
Phone
+905327608083
Email
hiozkan@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
hilal ozkan
Organizational Affiliation
Study director
Official's Role
Study Director
Facility Information:
Facility Name
Hilal Ozkan
City
Bursa
State/Province
Select...
ZIP/Postal Code
16285
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
hilal ozkan
Phone
05327608083
Email
hiozkan@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
21963186
Citation
Gopel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, Groneck P, Weller U, Moller J, Hartel C, Haller S, Roth B, Herting E; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011 Nov 5;378(9803):1627-34. doi: 10.1016/S0140-6736(11)60986-0. Epub 2011 Sep 29.
Results Reference
background
PubMed Identifier
27976361
Citation
Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD005384. doi: 10.1002/14651858.CD005384.pub2.
Results Reference
result

Learn more about this trial

Comparison of Efficacy of Less Invasive Surfactant Treatment Under Nasal CPAP and Nasal IPPV

We'll reach out to this number within 24 hrs